Trial Profile

Pilot Study Of Novel Combination Of Maraviroc + Atazanavir/Ritonavir vs. Atazanavir/Ritonavir + Emtricitabine/Tenofovir For The Treatment Of Naive HIV-Infected Patients With R5 HIV-1.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Maraviroc (Primary) ; Atazanavir/ritonavir; Emtricitabine/tenofovir disoproxil fumarate
Indications HIV-1 infections
Focus Therapeutic Use

Most Recent Events

31 Jan 2013 Primary endpoint 'Virological-response' has been met.
27 Jul 2012 Results presented at the 19th International AIDS Conference.
20 Jul 2011 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com